A user noted that a Phase I clinical trial for oral BPC-157 (under the name PCO-02) was initiated in 2015 to assess safety and pharmacokinetics but was canceled in 2016 without a public explanation. The user expressed concern that the cancellation could imply the substance was either ineffective or potentially dangerous.